Skip to content

Troponin T and Emergency High-risk Abdominal Surgery

Association of Cardiac and Inflammatory Bio Markers and Morbidity in Emergency High-risk Abdominal Surgery

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04878159
Enrollment
300
Registered
2021-05-07
Start date
2021-03-01
Completion date
2022-07-31
Last updated
2021-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Emergency Laparotomy, Inflammatory Response, Myocardial Injury

Brief summary

To assess whether perioperatively elevated TnT levels, using high sensitivity troponin T (hsTnT) measurements, are associated with an increased risk of postoperative mortality as well as severe postoperative complications.

Detailed description

Cardiac Troponin T (TnT) is a cardiac-specific molecule, released into the systemic circulation following myocardial cell injury. The release of cardiac Troponins is common during critical illness and is associated with increased morbidity and mortality. The mechanisms by which TnT is released in the blood during critical illness are not fully understood, but sepsis and inflammation are primary non-cardiac conditions during which elevated TnT levels are commonly seen. Previous research has shown that 84 percent of patients admitted to ICU had at least one elevated TnT measurement perioperatively. Patients undergoing high-risk abdominal surgery, defined as immediate emergency laparoscopy or laparotomy, are critically ill, often septic and with an acute inflammatory response and potential multiple organ system dysfunctions both prior but largely after surgery. The hypothesis is that there is an association between elevated perioperative levels of cardiac Troponin T and mortality in patients undergoing emergency high-risk abdominal surgery. The primary objective is to assess whether perioperatively elevated TnT levels, using high sensitivity troponin T (hsTnT) measurements, are associated with an increased risk of postoperative mortality as well as severe postoperative complications. Patients requiring immediate emergency laparotomy or laparoscopy, including reoperations after elective gastrointestinal surgery and reoperations after previous non emergency high-risk abdominal surgery surgery, will be included in the study. Two primary exposure measures will be investigated: 1. Peak Troponin T values ≥14 vs. Troponin T values \<14. Patients with at least one measured Troponin T value ≥14 postoperatively will be allocated to the elevated hsTnT group 2. Postoperative hsTnT concentration ≥14 as well as a \>50% relative increase from preoperative hsTnT concentration. Patients with hsTnT levels meeting these conditions will be allocated to the elevated hsTnT group hsTnT will be taken by blood samples preoperatively as well as on postoperative day 1, 2 and 3. Primary analyses investigating the association between hsTnT and 30-day mortality (yes/no) and severe complications (yes/no) will be done using logistic regression models.

Interventions

None listed

Sponsors

Copenhagen University Hospital, Hvidovre
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

Adults (18 years or over) undergoing emergency laparotomy or laparoscopy for following abdominal pathology: * Intestinal obstruction * Perforated viscus * Intestinal ischemia * Intraabdominal bleeding The above conditions include both primary surgery and re-operation after elective surgery.

Exclusion criteria

Patients undergoing * Appendicectomies * Negative laparoscopies/laparotomies * Cholecystectomies * Simple herniotomies following incarceration without bowel resection * Reoperation due to fascial separation with no other abdominal pathology identified * Internal hernia after Roux-en-Y gastric bypass surgery * Subacute surgery (surgery planned within 48 h) for inflammatory bowel diseases * Subacute colorectal cancer surgery * Patients with missing hsTnT values on both postoperative day 1 and 2

Design outcomes

Primary

MeasureTime frame
Death30 days
Severe complication (Clavien Dindo ≥ 3)30 days

Secondary

MeasureTime frame
Death90 days
Length of hospital stay30 days
Length of ICU stay30 days

Countries

Denmark

Contacts

Primary ContactSofia Kärnsund
sofia.paulina.kaernsund@regionh.dk+4528261925

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026